Working… Menu

Sun Protection Factor Assay (SPF Assay 18676) (SPF Assay)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02825030
Recruitment Status : Completed
First Posted : July 7, 2016
Last Update Posted : December 13, 2018
Information provided by (Responsible Party):

Brief Summary:
To evaluate the Sun Protection Factor efficacy on human skin.

Condition or disease Intervention/treatment Phase
Sunscreening Agent Drug: Coppertone (BAY 987516) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment- Darkening Dose.
Actual Study Start Date : December 10, 2015
Actual Primary Completion Date : December 17, 2015
Actual Study Completion Date : December 17, 2015

Arm Intervention/treatment
Experimental: Arm 1
Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
Drug: Coppertone (BAY 987516)
Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation-SR15-78_Y73-167).

Primary Outcome Measures :
  1. Minimal Erythema Dose (MED) [ Time Frame: Up to 15 minutes ]
  2. Minimal Persistent Pigment Darkening Dose (MPPD) [ Time Frame: Up to 15 minutes ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Fitzpatrick Skin Type l, ll and/or lll for UVB testing.
  • Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
  • Male and female
  • Aged between 18-70 years old.
  • Good health as determined from the HRL SHF
  • Signed and dated Informed Consent Form
  • Signed and dated HIPAA Form
  • An unambiguous MED or MPPD (Minimal Persistent Pigment Darkening Dose)

Exclusion Criteria:

  • Subjects on test at any other research laboratory or clinic.
  • Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
  • Pre-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
  • Pre-existing other medical conditions (e.g. adult asthma. diabetes).
  • Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
  • Treatment with antibiotics within two weeks prior to initiation of the test.
  • Chronic medication which could affect the results of the study.
  • Known pregnant or nursing women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02825030

Layout table for location information
United States, New Jersey
Union, New Jersey, United States, 07083
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT02825030    
Other Study ID Numbers: 18676
First Posted: July 7, 2016    Key Record Dates
Last Update Posted: December 13, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No